Peptide Bioavailability Research: Subcutaneous, Oral, IV, and Intranasal Delivery Compared

Administration route determines peak concentration, tissue distribution, onset, and duration of peptide action. Subcutaneous injection is the most common preclinical route, achieving near-complete bioavailability with sustained kinetics. IV achieves 100% bioavailability with immediate onset. Intranasal bypasses the blood-brain barrier via the olfactory route, making it uniquely relevant for CNS-targeted peptides. Oral delivery fails for most peptides due to proteolytic degradation, with BPC-157 as a notable exception. This article reviews the pharmacokinetic science underlying these differences for research context.

Bioavailability: The fraction of an administered dose that reaches systemic circulation in active form. IV = 100% by definition (reference standard). Subcutaneous, intranasal, and oral routes all have lower bioavailability.

Proteolytic degradation: The breakdown of peptides by endoproteases and exoproteases in the GI tract (pepsin, trypsin, chymotrypsin, peptidases), serum, and tissues. The primary barrier to oral peptide bioavailability.

First-pass effect: The hepatic metabolism of an absorbed compound before it reaches systemic circulation. Relevant to orally absorbed peptides that survive GI degradation: they still face hepatic enzymatic breakdown before reaching target tissues.

Subcutaneous absorption: Absorption through the hypodermis (fatty tissue under the skin) into capillaries and lymphatics. Rate-limited by capillary density and local blood flow at the injection site.

Blood-brain barrier (BBB): A selective permeability barrier formed by tight-junction-linked brain endothelial cells. Most peptides above approximately 500 Da cannot cross the BBB through passive diffusion.

Olfactory route: The pathway from the nasal epithelium through the cribriform plate of the ethmoid bone to the olfactory bulb. This allows compounds to bypass the BBB and enter the CNS directly from the nasal cavity.

Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated (ADME) by the body. Key pharmacokinetic parameters include Cmax (peak concentration), Tmax (time to peak), AUC (area under the concentration-time curve), and half-life.

The gastrointestinal tract is designed to digest proteins and peptides as nutrients. The same enzymatic machinery that breaks dietary protein into absorbable amino acids also destroys research peptides before they can be absorbed intact.

The degradation cascade begins in the stomach with pepsin (active at gastric pH 1-2), which cleaves peptide bonds adjacent to aromatic and hydrophobic residues. Surviving peptides encounter pancreatic enzymes in the duodenum: trypsin (cleaving after Lys and Arg), chymotrypsin (cleaving after aromatic residues), and elastase (cleaving after small aliphatic residues). Brush border peptidases in the intestinal epithelium further degrade remaining fragments.

Larger peptides (above approximately 1,000 Da) additionally face absorption barriers: they cannot cross the intestinal epithelium by passive diffusion efficiently, and active transport systems for large peptides are limited. Even if small amounts survive the proteolytic gauntlet, they face hepatic first-pass metabolism (portal blood delivers absorbed compounds to the liver before systemic circulation, where cytochrome P450 enzymes and peptidases provide another degradation stage).

For context on the peptides in the Blackwell research library, most have molecular weights in the 500-3,000 Da range and contain unprotected peptide bonds, making them highly susceptible to this cascade. See peptide administration routes and peptide half-life explained for additional pharmacokinetic context.

Subcutaneous (SC) injection is the most commonly used route in peptide preclinical research and remains a frequent route in clinical peptide trials. The SC compartment (the hypodermis, the layer of adipose and connective tissue beneath the dermis) absorbs peptides into the capillary and lymphatic networks via diffusion and convection.

SC bioavailability for most research peptides is estimated at 80-100%, approaching IV bioavailability without the technical requirements of intravenous access. The absorption kinetics are slower than IV: typical time to peak concentration (Tmax) is 15-45 minutes for small to medium peptides, with the absorption rate influenced by local blood flow, injection site, injection volume, and formulation.

The slower absorption kinetics produce a smoother, more sustained concentration-time profile compared to IV bolus, which may be pharmacologically advantageous for peptides where peak-to-trough ratio affects tolerability. Most preclinical peptide research uses SC injection for this combination of high bioavailability, controlled kinetics, and technical simplicity relative to IV.

For reference: BPC-157 protocol guide, GHK-Cu protocol guide, TB-500 protocol guide each contain specific administration context for those compounds.

Intravenous (IV) delivery achieves 100% bioavailability by definition (the reference standard) with immediate onset (Tmax essentially at injection). IV administration produces the highest achievable peak concentration (Cmax) of any route, which is pharmacologically important for compounds where tissue penetration, receptor saturation, or competitive inhibition depend on peak rather than average concentration.

Research contexts that favor IV include: cardiovascular studies where acute hemodynamic effects are the endpoint (where rapid onset is required); CNS acute injury models (TBI, stroke) where time-sensitive neuroprotection is studied; and pharmacokinetic studies where precise AUC calculation requires complete bioavailability as the starting point for bioavailability estimation of other routes.

Limitations of IV include technical complexity (vascular access, sterile preparation, injection volume limits), risk of injection site reactions with impure preparations (particularly relevant for research compounds where sterility and endotoxin testing must be verified), and the short-duration, high-peak-then-rapid-decline kinetics which may not match the physiological patterning of the compound being studied.

Cerebrolysin is a prominent example of a peptide compound typically administered IV in clinical research (30-50 mL IV infusion). The Cerebrolysin guide and Cerebrolysin clinical evidence provide context on IV peptide administration in clinical trial settings.

The olfactory epithelium, which lines the upper nasal cavity, is the only location in the human body where the CNS is directly exposed to the external environment via nerve tissue rather than via the blood. Olfactory sensory neurons pass through the cribriform plate of the ethmoid bone, providing a direct anatomical pathway from the nasal cavity to the olfactory bulb and, from there, to the rest of the CNS.

Compounds deposited on the olfactory epithelium can travel to the CNS via three routes: transcellular transport through olfactory neurons (axonal transport), paracellular transport through the perineural spaces, and transcellular transport through sustentacular (supporting) cells. This olfactory route bypasses the blood-brain barrier and can deliver peptides to CNS targets at concentrations that would not be achievable after systemic administration and BBB crossing.

Intranasal bioavailability is highly variable: published data shows a range from approximately 1% to 50%+ for different compounds, depending on molecular weight, physicochemical properties, mucociliary clearance, and formulation. For CNS-targeted peptides, the relevant question is not total systemic bioavailability but CNS bioavailability specifically, which the olfactory route may deliver disproportionately efficiently.

Semax and Selank are the clearest examples of intranasal peptide delivery in a clinical context. Both are registered as intranasal formulations in Russia for CNS indications, with established clinical dosing via this route. Their clinical success validates intranasal peptide delivery as a pharmacologically viable route for CNS-targeted compounds. See Semax guide and Selank guide.

The oral bioavailability limitations described above apply to the vast majority of research peptides. However, exceptions exist that are pharmacologically important.

BPC-157 is the most notable exception in the Blackwell research library. Published research from the Zagreb group demonstrates that BPC-157 maintains biological activity when administered orally, including in models where oral administration produces effects in tissues far from the GI tract. The proposed explanation is unusual stability of BPC-157 against gastric acid and GI proteases: its specific amino acid sequence and conformation may resist the proteolytic cascade that destroys most peptides in the GI environment.

Published data includes oral BPC-157 studies with systemic endpoints (healing of peripheral injury sites, neuroprotection) that suggest meaningful systemic bioavailability despite oral administration. The mechanism of this unusual oral stability has not been fully characterized.

Insulin provides a historical example of oral peptide delivery research. Despite decades of research, reliable oral insulin delivery remains challenging and requires specialized formulations. This illustrates the difficulty of overcoming GI proteolysis even for extensively studied peptides.

For BPC-157 research context: BPC-157 guide, BPC-157 human evidence review.

The choice of administration route is not merely a technical detail: it directly determines which research outcomes can be studied and how results should be interpreted.

CNS-targeted research: For peptides studied for cognitive, neuroprotective, or neurological effects, intranasal delivery is often specifically relevant because it achieves CNS concentrations that systemic routes may not. Comparing IV or SC data to intranasal data for CNS-targeted peptides is not straightforward because the tissue distribution profiles differ substantially.

GI-targeted research: For gut-specific research (IBD, gastroprotection, mucosal healing), oral delivery may be the pharmacologically appropriate route regardless of systemic bioavailability, because the relevant target tissue is the GI tract itself. BPC-157 oral research in IBD models is an example: the GI distribution matters more than systemic bioavailability.

Cardiovascular research: IV route is frequently used because cardiovascular pharmacology often involves acute hemodynamic effects and rapid distribution to cardiac tissue, which is better served by IV kinetics than sustained SC absorption.

Systemic anti-inflammatory or healing research: SC is typically adequate and practically superior to IV, with comparable bioavailability and simpler administration.

A structured comparison of the four primary peptide administration routes:

Researchers designing peptide studies should match the administration route to the research question rather than defaulting to a single route for all applications.

For CNS or cognitive endpoint studies (memory, neuroprotection, mood, neurological injury): intranasal or IV routes are most appropriate, as they achieve CNS concentrations more reliably than SC. Semax and Selank's clinical validation via intranasal route provides a research framework for other CNS-targeted peptide studies.

For peripheral tissue repair or systemic anti-inflammatory studies (tendon, wound healing, metabolic, cardiovascular, immune): SC is typically the most practical route with near-complete bioavailability. Most published BPC-157, TB-500, and GHK-Cu animal research uses SC or IP injection.

For pharmacokinetic characterization studies: IV is required as the reference bioavailability standard. Comparing AUC after IV with AUC after other routes quantifies absolute bioavailability of those routes for a specific compound.

For GI-specific research (IBD, gastric healing, gut permeability): oral delivery is appropriate as the GI tract is the target tissue, regardless of systemic bioavailability. Published BPC-157 oral IBD data exemplifies this.

See peptide administration routes, peptide half-life explained, and how to reconstitute peptides for related practical context.